Novartis wins approval for meningitis vaccine
Swiss pharmaceutical group Novartis says it has won approval by the European Union's medicines agency for its Bexsero vaccine against meningitis B infections, the first broad coverage jab of its kind.
"Bexsero will be the first licensed broad coverage vaccine that can help protect all age groups against MenB (Meningococcal serogroup B) disease, including infants, the age group at the greatest risk of infection," Novartis said in a statement on Friday.
Current vaccines offer protection for several types of the disease that causes an inflammation of the membranes covering the brain and spinal cord, but not against MenB, which accounts for up to 90 percent of all cases of the disease in some European countries, the company said.
"MenB disease is easily misdiagnosed, can kill within 24 hours and may cause serious, life-long disabilities," Novartis said.
The highest rates of the disease occur the first year of life, peaking by seven months of age, the company said.
A final decision on whether the vaccine can be launched throughout the European Union and European Economic Area must be announced within three months by the European Commission, Novartis said.
It said EU chiefs usually followed the recommendations of the Committee for Medicinal Products for Human Use (CHMP).
Approximately 1.2 million cases of invasive meningococcal disease are recorded worldwide, and 7,000 occur in Europe, according to the European Medicines Agency (EMA) which approved the vaccine.
Of the 13 meningococcal types, EMA said, in Europe group B is the most prevalent, with 3,406-4,819 cases reported annually between 2003 and 2007.
Comments
See Also
"Bexsero will be the first licensed broad coverage vaccine that can help protect all age groups against MenB (Meningococcal serogroup B) disease, including infants, the age group at the greatest risk of infection," Novartis said in a statement on Friday.
Current vaccines offer protection for several types of the disease that causes an inflammation of the membranes covering the brain and spinal cord, but not against MenB, which accounts for up to 90 percent of all cases of the disease in some European countries, the company said.
"MenB disease is easily misdiagnosed, can kill within 24 hours and may cause serious, life-long disabilities," Novartis said.
The highest rates of the disease occur the first year of life, peaking by seven months of age, the company said.
A final decision on whether the vaccine can be launched throughout the European Union and European Economic Area must be announced within three months by the European Commission, Novartis said.
It said EU chiefs usually followed the recommendations of the Committee for Medicinal Products for Human Use (CHMP).
Approximately 1.2 million cases of invasive meningococcal disease are recorded worldwide, and 7,000 occur in Europe, according to the European Medicines Agency (EMA) which approved the vaccine.
Of the 13 meningococcal types, EMA said, in Europe group B is the most prevalent, with 3,406-4,819 cases reported annually between 2003 and 2007.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.